Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Simak Ali

Showing results (101-110 of 111) with videos related to

Pageof 12
Sort By:
Journal of Medicinal Chemistry|November 18, 2010
A novel pyrazolo[1,5-a]pyrimidine is a potent inhibitor of cyclin-dependent protein kinases 1, 2, and 9, which demonstrates antitumor effects in human tumor xenografts following oral administrationDean A Heathcote, Hetal Patel, Sebastian H B Kroll, et al.
Cancer Research|March 21, 2020
Endonuclease FEN1 Coregulates ERα Activity and Provides a Novel Drug Interface in Tamoxifen-Resistant Breast CancerKoen D Flach, Manikandan Periyasamy, Ajit Jadhav, et al.
Oncotarget|August 18, 2015
Expression profiling of nuclear receptors in breast cancer identifies TLX as a mediator of growth and invasion in triple-negative breast cancerMeng-Lay Lin, Hetal Patel, Judit Remenyi, et al.
Nature Communications|April 20, 2022
ESR1 mutant breast cancers show elevated basal cytokeratins and immune activationZheqi Li, Olivia McGinn, Yang Wu, et al.
Nature Communications|December 2, 2017
Discovery of naturally occurring ESR1 mutations in breast cancer cell lines modelling endocrine resistanceLesley-Ann Martin, Ricardo Ribas, Nikiana Simigdala, et al.
Iscience|May 25, 2026
Distinct 2-phenylimidazo[1,2-<i>a</i>]pyridine derivatives that inhibit breast cancer cell proliferation identified as AHR ligandsKatrin Koellisch, Christine Blattner, Stefano Motta, et al.
JCO Precision Oncology|May 1, 2024
Serial Postoperative Circulating Tumor DNA Assessment Has Strong Prognostic Value During Long-Term Follow-Up in Patients With Breast CancerJacqueline A Shaw, Karen Page, Evie Wren, et al.
Journal of Natural Products|June 20, 2025
Modulation of Estrogen Receptor Activity by the Phytoalexin Tuberosin Produced from Elicited Kudzu (<i>Pueraria lobata</i>)Jorge A Belgodere, Jack R Elliott, Megan C Benz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 18, 2019
Personalized Detection of Circulating Tumor DNA Antedates Breast Cancer Metastatic RecurrenceRaoul Charles Coombes, Karen Page, Raheleh Salari, et al.
Cancer Research|January 26, 2022
Hotspot ESR1 Mutations Are Multimodal and Contextual Modulators of Breast Cancer MetastasisZheqi Li, Yang Wu, Megan E Yates, et al.
Pageof 12

Showing results (101-110 of 111) with videos related to

Sort By:
Pageof 12
Journal of Medicinal Chemistry|November 18, 2010
A novel pyrazolo[1,5-a]pyrimidine is a potent inhibitor of cyclin-dependent protein kinases 1, 2, and 9, which demonstrates antitumor effects in human tumor xenografts following oral administrationDean A Heathcote, Hetal Patel, Sebastian H B Kroll, et al.
Cancer Research|March 21, 2020
Endonuclease FEN1 Coregulates ERα Activity and Provides a Novel Drug Interface in Tamoxifen-Resistant Breast CancerKoen D Flach, Manikandan Periyasamy, Ajit Jadhav, et al.
Oncotarget|August 18, 2015
Expression profiling of nuclear receptors in breast cancer identifies TLX as a mediator of growth and invasion in triple-negative breast cancerMeng-Lay Lin, Hetal Patel, Judit Remenyi, et al.
Nature Communications|April 20, 2022
ESR1 mutant breast cancers show elevated basal cytokeratins and immune activationZheqi Li, Olivia McGinn, Yang Wu, et al.
Nature Communications|December 2, 2017
Discovery of naturally occurring ESR1 mutations in breast cancer cell lines modelling endocrine resistanceLesley-Ann Martin, Ricardo Ribas, Nikiana Simigdala, et al.
Iscience|May 25, 2026
Distinct 2-phenylimidazo[1,2-<i>a</i>]pyridine derivatives that inhibit breast cancer cell proliferation identified as AHR ligandsKatrin Koellisch, Christine Blattner, Stefano Motta, et al.
JCO Precision Oncology|May 1, 2024
Serial Postoperative Circulating Tumor DNA Assessment Has Strong Prognostic Value During Long-Term Follow-Up in Patients With Breast CancerJacqueline A Shaw, Karen Page, Evie Wren, et al.
Journal of Natural Products|June 20, 2025
Modulation of Estrogen Receptor Activity by the Phytoalexin Tuberosin Produced from Elicited Kudzu (<i>Pueraria lobata</i>)Jorge A Belgodere, Jack R Elliott, Megan C Benz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 18, 2019
Personalized Detection of Circulating Tumor DNA Antedates Breast Cancer Metastatic RecurrenceRaoul Charles Coombes, Karen Page, Raheleh Salari, et al.
Cancer Research|January 26, 2022
Hotspot ESR1 Mutations Are Multimodal and Contextual Modulators of Breast Cancer MetastasisZheqi Li, Yang Wu, Megan E Yates, et al.
Pageof 12